Literature DB >> 9815715

Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies.

K Watanabe1, K Sato, W Biernat, O Tachibana, K von Ammon, N Ogata, Y Yonekawa, P Kleihues, H Ohgaki.   

Abstract

Mutations of the p53 tumor suppressor gene are a genetic hallmark of human astrocytic neoplasms, but their predictive role in glioma progression is still poorly understood. We analyzed 144 biopsies from 67 patients with recurrent astrocytoma by single-strand conformation polymorphism and direct DNA sequencing. We found that 46 of 67 patients (69%) had a p53 mutation in at least one biopsy. In 41 of these (89%), the mutation was already present in the first biopsy, indicating that p53 mutations are early events in the evolution of diffuse astrocytomas. Double mutations of the p53 gene were observed in three tumors and also present from the first biopsy. Of 28 low-grade astrocytomas with a p53 mutation, 7 (25%) showed loss of the normal allele in the first biopsy. The allele status remained the same in 95% of the cases, irrespective of whether the recurrent lesion had the same or a higher grade of malignancy. Progression of low-grade astrocytomas to anaplastic astrocytoma or glioblastoma occurred at a similar frequency in lesions with (79%) and without (63%) p53 mutations (P = 0.32), indicating that this genetic alteration is associated with tumor recurrence but not predictive of progression to a more malignant phenotype. However, the time interval until progression was shorter in patients with low-grade astrocytomas carrying a p53 mutation (P = 0.055).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9815715

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  55 in total

Review 1.  Brain tumours: classification and genes.

Authors:  V P Collins
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-06       Impact factor: 10.154

2.  Gemistocytes in astrocytomas: are they a significant prognostic factor?

Authors:  Dely C Martins; Suzana M Malheiros; Lucila H Santiago; João N Stávale
Journal:  J Neurooncol       Date:  2006-04-28       Impact factor: 4.130

3.  Secondary glioblastoma with advanced neuronal immunophenotype.

Authors:  Junji Shibahara; Masashi Fukayama
Journal:  Virchows Arch       Date:  2005-06-21       Impact factor: 4.064

4.  Glioblastoma multiforme: Molecular characterization and current treatment strategy (Review).

Authors:  Xiang Zhang; Wei Zhang; Wei-Dong Cao; Gang Cheng; Yong-Qiang Zhang
Journal:  Exp Ther Med       Date:  2011-10-18       Impact factor: 2.447

5.  TP53 promoter methylation in primary glioblastoma: relationship with TP53 mRNA and protein expression and mutation status.

Authors:  Dorota Jesionek-Kupnicka; Malgorzata Szybka; Beata Malachowska; Wojciech Fendler; Piotr Potemski; Sylwester Piaskowski; Dariusz Jaskolski; Wielislaw Papierz; Wieslaw Skowronski; Waldemar Och; Radzislaw Kordek; Izabela Zawlik
Journal:  DNA Cell Biol       Date:  2014-02-07       Impact factor: 3.311

6.  Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.

Authors:  Brett E Johnson; Tali Mazor; Chibo Hong; Michael Barnes; Koki Aihara; Cory Y McLean; Shaun D Fouse; Shogo Yamamoto; Hiroki Ueda; Kenji Tatsuno; Saurabh Asthana; Llewellyn E Jalbert; Sarah J Nelson; Andrew W Bollen; W Clay Gustafson; Elise Charron; William A Weiss; Ivan V Smirnov; Jun S Song; Adam B Olshen; Soonmee Cha; Yongjun Zhao; Richard A Moore; Andrew J Mungall; Steven J M Jones; Martin Hirst; Marco A Marra; Nobuhito Saito; Hiroyuki Aburatani; Akitake Mukasa; Mitchel S Berger; Susan M Chang; Barry S Taylor; Joseph F Costello
Journal:  Science       Date:  2013-12-12       Impact factor: 47.728

7.  Novel dual-reporter preclinical screen for antiastrocytoma agents identifies cytostatic and cytotoxic compounds.

Authors:  Jessica J Hawes; John D Nerva; Karlyne M Reilly
Journal:  J Biomol Screen       Date:  2008-07-29

8.  High frequency of temperature-sensitive mutants of p53 in glioblastoma.

Authors:  Jana Smardova; Kvetoslava Liskova; Barbora Ravcukova; Lenka Kubiczkova; Sabina Sevcikova; Jaroslav Michalek; Miluse Svitakova; Vaclav Vybihal; Leos Kren; Jan Smarda
Journal:  Pathol Oncol Res       Date:  2013-03-28       Impact factor: 3.201

9.  Mesenchymal migration as a therapeutic target in glioblastoma.

Authors:  Jessie Zhong; Andre Paul; Stewart J Kellie; Geraldine M O'Neill
Journal:  J Oncol       Date:  2010-06-21       Impact factor: 4.375

Review 10.  Genetic pathways to primary and secondary glioblastoma.

Authors:  Hiroko Ohgaki; Paul Kleihues
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.